Effects of orlistat on the viability of human gallbladder cancer cells

Cheng Haihong; Sun Yuxin; Yu Xiaopeng; Wang Shouhua; Ding Jun; Zhou Di; Zhang Xiaoyu; Wang Jiandong; Shi Weibin; Ma Fei

doi:10.3760/cma.j.cn115610-20230404-00149

Chinese Journal of Digestive Surgery > 2023 > 22(5): 636-641. > DOI: 10.3760/cma.j.cn115610-20230404-00149

Cheng Haihong, Sun Yuxin, Yu Xiaopeng, et al. Effects of orlistat on the viability of human gallbladder cancer cells[J]. Chinese Journal of Digestive Surgery, 2023, 22(5): 636-641. DOI: 10.3760/cma.j.cn115610-20230404-00149

Citation:

PDF

Effects of orlistat on the viability of human gallbladder cancer cells

1.
Department of Oncology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai200092, China
2.
Department of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai200092, China
3.
Department of Biliary and Pancreatic Surgery, Shanghai Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai201203, China
4.
Department of Hepatobiliary Surgery, Tenth People's Hospital of Tongji University, Shanghai200072, China

Funds:

Special Project of Clinical Research of Shanghai Municipal Health Commission 202040447

More Information

Corresponding author:
Ma Fei, Email: mafei@xinhuamed.com.cn
Received Date: April 03, 2023
Available Online: June 24, 2024

Graphical Abstract

Abstract

Abstract

Objective
To investigate the effects of orlistat on the viability of human gall-bladder cancer (GBC) cells.
Methods
The experimental study was conducted. The human GBC NOZ cells with high expression of FSAN was screened out through in vitro cultivating human GBC-SD, SGC-996 and NOZ cells. The cell proliferation assay, clone formation assay and protein detection experiment were used to analysis of the effects of orlistat on the viability of human GBC cells. Cell grouping: NOZ cells cultured with medium were set as the control group, cultured with medium + 10 μmol/L orlistat were set as the low-dose orlistat group, cultured with medium + 100 μmol/L orlistat were set as the high-dose orlistat group, respectively. Observation indicators: (1) expression of FASN protein in human GBC cells; (2) effects of orlistat on the proliferation of human GBC NOZ cells; (3) effects of orlistat on apoptosis of human GBC NOZ cells. Measurement data with normal distribution were represented as Mean±SD, the ANOVA test was used for comparison between groups and the least significant difference method was used for pairwise comparison.
Results
(1) Expression of FASN protein in human GBC cells. Results of western blot showed that the relative expression of FASN protein in human GBC NOZ, GBC-SD and SGC-996 cells was 0.57±0.06, 0.12±0.04 and 0.10±0.02, respectively, showing a significant difference among them (F=115.67, P<0.05). There were significant differences between the NOZ cells and the GBC-SD or the SGC-996 cells (P<0.05), and there was no significant difference between the GBC-SD cells and the SGC-996 cells (P>0.05). (2) Effects of orlistat on the proliferation of human GBC NOZ cells. ① Results of cell proliferation assay showed that the absorbance value of NOZ cells was 2.34±0.12, 1.57±0.08 and 1.07±0.13 in the control group, low-dose orlistat group and high-dose orlistat group, respectively, showing a significant difference among them (F=205.88, P<0.05). ② Results of clone formation assay showed that the number of NOZ cells clones was 257±23, 153±11 and 83±11 in the control group, low-dose orlistat group and high-dose orlistat group, respectively, showing a significant difference among them (F=92.64, P<0.05). ③Results of western blot showed that the relative expression of Cyclin-D1 protein of NOZ cells was 2.31±0.10, 1.52±0.05 and 1.23±0.11 in the control group, low-dose orlistat group and high-dose orlistat group, respectively, showing a significant difference among them (F=120.73, P<0.05). The relative expression of CDK-4 protein of NOZ cells was 1.58±0.04, 1.21±0.02 and 1.19±0.04 in the control group, low-dose orlistat group and high-dose orlistat group, respectively, showing a signifi-cant difference among them (F=110.45, P<0.05). (3) Effects of orlistat on apoptosis of human GBC NOZ cells. Results of western blot showed that the relative expression of Bcl-2 protein of NOZ cells was 1.07±0.03, 0.36±0.03 and 0.15±0.02 in the control group, low-dose orlistat group and high-dose orlistat group, respectively, showing a significant difference among them (F=1 242.93, P<0.05). The relative expression of Bax protein of NOZ cells was 0.51±0.03, 0.38±0.05 and 1.38±0.04 in the control group, low-dose orlistat group and high-dose orlistat group, respectively, showing a signifi-cant difference among them (F=583.51, P<0.05).
Conclusion
Orlistat can inhibit the growth of human GBC NOZ cells and promote their apoptosis.
- Gallbladder neoplasms,
- Orlistat,
- Cell proliferation,
- Cell apoptosis,
- Cell viability,
- Cyclins,
- Apoptosis-related proteins

FullText(HTML)

References (41)

References

[1]	Lazcano‑PonceEC, MiquelJF, MuñozN, et al. Epidemiology and molecular pathology of gallbladder cancer[J]. CA Cancer J Clin,2001,51(6):349‑364. DOI:10.3322/canjclin. 51.6.349.
[2]	SharmaA, SharmaKL, GuptaA, et al. Gallbladder cancer epidemiology, pathogenesis and molecular genetics: recent update[J]. World J Gastroenterol,2017,23(22):3978‑3998. DOI: 10.3748/wjg.v23.i22.3978.
[3]	RoaJC, GarcíaP, KapoorVK, et al. Gallbladder cancer[J]. Nat Rev Dis Primers,2022,8(1):69. DOI: 10.1038/s41572-022-00398-y.
[4]	FeoCF, GinesuGC, FancelluA, et al. Current management of incidental gallbladder cancer: a review[J]. Int J Surg,2022,98:106234. DOI: 10.1016/j.ijsu.2022.106234.
[5]	Gallbladder cancer[J]. Nat Rev Dis Primers,2022,8(1):70. DOI: 10.1038/s41572-022-00403-4.
[6]	OuyangG, LiuQ, WuY, et al. The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Cancer,2021,127(13):2238‑2250. DOI: 10.1002/cncr.33476.
[7]	NakamuraH, AraiY, TotokiY, et al. Genomic spectra of biliary tract cancer[J]. Nat Genet,2015,47(9):1003‑1010. DOI: 10.1038/ng.3375.
[8]	MoeiniA, HaberPK, SiaD. Cell of origin in biliary tract cancers and clinical implications[J]. JHEP Rep,2021,3(2):100226. DOI: 10.1016/j.jhepr.2021.100226.
[9]	SungH, FerlayJ, SiegelRL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021, 71(3):209‑249. DOI: 10.3322/caac.21660.
[10]	RakićM, PatrljL, KopljarM, et al. Gallbladder cancer[J]. Hepatobiliary Surg Nutr,2014,3(5):221‑226. DOI:10.39 78/j.issn.2304-3881.2014.09.03.
[11]	ParkK, KimKP, ParkS, et al. Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer[J]. Asia Pac J Clin Oncol,2017,13(1):13‑20. DOI:10.1111/ajco. 12592.
[12]	OkusakaT, NakachiK, FukutomiA, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan[J]. Br J Cancer,2010,103(4):469‑474. DOI:10.1038/sj.bjc.66 0 5779.
[13]	ValleJ, WasanH, PalmerDH, et al. Cisplatin plus gemci-tabine versus gemcitabine for biliary tract cancer[J]. N Engl J Med,2010,362(14):1273‑1281. DOI:10.1056/NEJ Moa0908721.
[14]	PhelipJM, DesrameJ, EdelineJ, et al. Modified FOLFIRINOX versus CISGEM chemotherapy for patients with advanced biliary tract cancer (PRODIGE 38 AMEBICA): a randomi-zed phase Ⅱ study[J]. J Clin Oncol,2022,40(3):262‑271. DOI: 10.1200/JCO.21.00679.
[15]	JovankićJV, NikodijevićDD, MilutinovićMG, et al. Potential of Orlistat to induce apoptotic and antiangiogenic effects as well as inhibition of fatty acid synthesis in breast cancer cells[J]. Eur J Pharmacol,2023,939:175456. DOI: 10.1016/j.ejphar.2022.175456.
[16]	PallaschCP, SchwambJ, KönigsS, et al. Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B‑cell chronic lymphocytic leukemia cells[J]. Leukemia,2008,22(3):585‑592. DOI: 10.1038/sj.leu.2405058.
[17]	SnaebjornssonMT, Janaki‑RamanS, SchulzeA. Greasing the wheels of the cancer machine: the role of lipid metabo-lism in cancer[J]. Cell Metab,2020,31(1):62‑76. DOI:10.10 16/j.cmet.2019.11.010.
[18]	StoykovaGE, SchlaepferIR. Lipid metabolism and endocrine resistance in prostate cancer, and new opportunities for therapy[J]. Int J Mol Sci,2019,20(11):2626. DOI: 10.3390/ijms20112626.
[19]	ChengC, GengF, ChengX, et al. Lipid metabolism reprogramming and its potential targets in cancer[J]. Cancer Commun (Lond),2018,38(1):27. DOI: 10.1186/s40880-018-0301-4.
[20]	CaoY. Adipocyte and lipid metabolism in cancer drug resistance[J]. J Clin Invest,2019,129(8):3006‑3017. DOI: 10.1172/JCI127201.
[21]	BianX, LiuR, MengY, et al. Lipid metabolism and cancer[J]. J Exp Med,2021,218(1):e20201606. DOI:10.1084/jem. 20201606.
[22]	YoonH, LeeS. Fatty acid metabolism in ovarian cancer: therapeutic implications[J]. Int J Mol Sci,2022,23(4):2170. DOI: 10.3390/ijms23042170.
[23]	Martin‑PerezM, Urdiroz‑UrricelquiU, BigasC, et al. The role of lipids in cancer progression and metastasis[J]. Cell Metab,2022,34(11):1675‑1699. DOI:10.1016/j.cmet.2022. 09.023.
[24]	KerekesDM, KhanSA. Lipid metabolism in biliary tract cancer: a new therapeutic target?[J]. Ann Surg Oncol,2022,29(5):2750‑2751. DOI: 10.1245/s10434-022-11383-w.
[25]	WangF, WangB, QiaoL. Association between obesity and gallbladder cancer[J]. Front Biosci (Landmark Ed),2012,17(7):2550‑2558. DOI: 10.2741/4070.
[26]	PatiS, IrfanW, JameelA, et al. Obesity and cancer: a current overview of epidemiology, pathogenesis, outcomes, and management[J]. Cancers (Basel),2023,15(2):485. DOI:10. 3390/cancers15020485.
[27]	SharmaN, YadavM, TripathiG, et al. Bile multi‑omics ana-lysis classifies lipid species and microbial peptides predictive of carcinoma of gallbladder[J]. Hepatology,2022,76(4):920‑935. DOI: 10.1002/hep.32496.
[28]	ShiY, FanY, HuY, et al. α‑Mangostin suppresses the de novo lipogenesis and enhances the chemotherapeutic res-ponse to gemcitabine in gallbladder carcinoma cells via targeting the AMPK/SREBP1 cascades[J]. J Cell Mol Med,2020,24(1):760‑771. DOI: 10.1111/jcmm.14785.
[29]	Schcolnik‑CabreraA, Chávez‑BlancoA, Domínguez-GómezG, et al. Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy[J]. Expert Opin Investig Drugs,2018,27(5):475‑489. DOI: 10.1080/13543784.2018.1471132.
[30]	PaulmuruganR, BhethanabotlaR, MishraK, et al. Folate receptor‑targeted polymeric micellar nanocarriers for deli-very of orlistat as a repurposed drug against triple-negative breast cancer[J]. Mol Cancer Ther,2016,15(2):221‑231. DOI: 10.1158/1535-7163.MCT-15-0579.
[31]	MimsJ, BansalN, BharadwajMS, et al. Energy metabolism in a matched model of radiation resistance for head and neck squamous cell cancer[J]. Radiat Res,2015,183(3):291-304. DOI: 10.1667/RR13828.1.
[32]	MenendezJA, VellonL, LupuR. The antiobesity drug Orlistat induces cytotoxic effects, suppresses Her‑2/neu (erbB‑2) oncogene overexpression, and synergistically interacts with trastuzumab (Herceptin) in chemoresistant ovarian cancer cells[J]. Int J Gynecol Cancer,2006,16(1):219‑221. DOI: 10.1111/j.1525-1438.2006.00297.x.
[33]	KnowlesLM, YangC, OstermanA, et al. Inhibition of fatty-acid synthase induces caspase‑8‑mediated tumor cell apo-ptosis by up‑regulating DDIT4[J]. J Biol Chem,2008,283(46):31378‑31384. DOI: 10.1074/jbc.M803384200.
[34]	FujiwaraJ, SowaY, HorinakaM, et al. The anti‑obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone‑refractory prostate cancer cells[J]. Int J Oncol,2016,48(2):854. DOI: 10.3892/ijo.2015.3265.
[35]	MenendezJA, LupuR. RNA interference‑mediated silencing of the p53 tumor‑suppressor protein drastically increa-ses apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells[J]. Int J Mol Med,2005,15(1):33‑40.
[36]	KnowlesLM, AxelrodF, BrowneCD, et al. A fatty acid synthase blockade induces tumor cell‑cycle arrest by down-regulating Skp2[J]. J Biol Chem,2004,279(29):30540-30545. DOI: 10.1074/jbc.M405061200.
[37]	AgostiniM, AlmeidaLY, BastosDC, et al. The fatty acid syn-thase inhibitor orlistat reduces the growth and metastasis of orthotopic tongue oral squamous cell carcinomas[J]. Mol Cancer Ther,2014,13(3):585‑595. DOI: 10.1158/1535-7163.MCT-12-1136.
[38]	Cervantes‑MadridD, Dueñas‑GonzálezA. Antitumor effects of a drug combination targeting glycolysis, glutaminolysis and de novo synthesis of fatty acids[J]. Oncol Rep,2015,34(3):1533‑1542. DOI: 10.3892/or.2015.4077.
[39]	CarvalhoMA, ZecchinKG, SeguinF, et al. Fatty acid synthase inhibition with Orlistat promotes apoptosis and reduces cell growth and lymph node metastasis in a mouse melanoma model[J]. Int J Cancer,2008,123(11):2557-2565. DOI: 10.1002/ijc.23835.
[40]	KridelSJ, AxelrodF, RozenkrantzN, et al. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity[J]. Cancer Res,2004,64(6):2070‑2075. DOI: 10.1158/0008-5472.can-03-3645.
[41]	ChoiE, KimE, KimJH, et al. AKT1‑targeted proapoptotic activity of compound K in human breast cancer cells[J]. J Ginseng Res,2019,43(4):692‑698. DOI:10.1016/j.jgr.2019. 07.001.

[1]	Gu Yongpeng, Liu Jie, Zhu Zhenbao, Wu Di, Xie Chuanming, Zhang Leida. Expression of nucleoporin 43 in hepatocellular carcinoma tissues and its impact on prognosis of patients and proliferation and migration of hepatocellular carcinoma cells[J]. Chinese Journal of Digestive Surgery, 2024, 23(11): 1437-1444. DOI: 10.3760/cma.j.cn115610-20241026-00468
[2]	Ma Haidong, Cao Jie, Gao Long, Fu Wenkang, Mi Ningning, Bai Mingzhen, Lin Yanyan, Su Gang, Kou Wen, Meng Wenbo. The influence of glucose regulatory protein 78 on prognosis and tumor cell proliferation of hepatocellular carcinoma[J]. Chinese Journal of Digestive Surgery, 2021, 20(12): 1294-1305. DOI: 10.3760/cma.j.cn115610-20211008-00492
[3]	Jiang Yan, Liu Wei, Chen Zhiyu. Mechanisms of tumor necrosis factorrelated apoptosis inducing ligandcombined with Triptolide in inducing the apoptosis of pancreatic cancer cells[J]. Chinese Journal of Digestive Surgery, 2015, 14(4): 321-328. DOI: 10.3760/cma.j.issn.1673-9752.2015.04.013
[4]	CHEN Hong jin *, GU Yun fei, CHEN Yu gen, ZHANG Shu peng, ZHU Ping, LIN Qiu, YANG Bo lin. Effects of baicalin on the apoptosis and cell cycle of colorectal cancer cells in orthotopic transplantation mice model with mismatch repair gene deficient[J]. Chinese Journal of Digestive Surgery, 2013, 12(6): 435-439. DOI: 10.3760/cma.j.issn.1673-9752.2013.06.009
[5]	SHI Yong qiang, LIU Li xin, ZHANG Hai yan, ZHANG Qian qian. Effect of insulin like growth factor binding protein related protein 1 in the formation and development of hepatic fibrosis[J]. Chinese Journal of Digestive Surgery, 2010, 9(5): 377-382.
[6]	LIU Hong bin, QIAN Jun bo, YANG Qi chang, TU Xin li, ZHU Yan, SHEN Yi. Relationship between the co expression of CD105 and cyclin D1 and lymph node metastasis and prognosis of esophageal squamous cell carcinoma[J]. Chinese Journal of Digestive Surgery, 2010, 9(4): 280-282.
[7]	CUI Yan *, DONG Jia hong, ZHOU Jin lian, ZHANG Ming, LI Cheng lin, LIU Zi pei, YI Yong, ZHANG Jianzhong. Effects of weightlessness on the apoptosis of hepatocytes in rats[J]. Chinese Journal of Digestive Surgery, 2010, 9(1): 52-54.
[8]	MAO Jia ding, WU Pei, YANG Ying lin, WU Jian, HUANG He. Effects of somatostatin on the apoptosis of colorectal cancer cells[J]. Chinese Journal of Digestive Surgery, 2009, 8(5): 360-363.
[9]	LIU li xin *, ZHANG Qian qian, GUO Xiao hong, ZHAO Jia hui, HAN Dewu. Expression and significance of insulin like growth factor binding protein related protein 1 in activated hepatic stellate cell[J]. Chinese Journal of Digestive Surgery, 2008, 7(1): 49-52.
[10]	CHEN Jian, LI Da jiang, WANG Shu guang. Effect of adenovirus mediated apoptin gene on apoptosis of human bile duct carcinoma cells[J]. Chinese Journal of Digestive Surgery, 2007, 6(4): 294-298.

Cited By

Get Citation

PDF

XML

Article views (83) PDF downloads (0)

Turn off MathJax

Article Contents

Abstract

References

Effects of orlistat on the viability of human gallbladder cancer cells

Abstract

References

Related Articles

Catalog

Journal Info

For Authors

For Reviewers

Ethics and Policies

Archives

Special Issues

Effects of orlistat on the viability of human gallbladder cancer cells

Abstract

References

Related Articles

Catalog

Journal Info

For Authors

For Reviewers

Ethics and Policies

Archives

Special Issues

Export File

Citation

Format

Content